Rabbit Polyclonal SENP2 antibody. Suitable for WB, IHC-P, ICC/IF and reacts with Human samples. Cited in 1 publication. Immunogen corresponding to Synthetic Peptide within Human SENP2 aa 1-50.
pH: 7
Preservative: 0.01% Thimerosal (merthiolate)
Constituents: 78.99% PBS, 20% Glycerol (glycerin, glycerine), 1% BSA
WB | IHC-P | ICC/IF | |
---|---|---|---|
Human | Tested | Tested | Tested |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/500.00000 - 1/3000.00000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/100.00000 - 1/500.00000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/100.00000 - 1/200.00000 | Notes - |
Select an associated product type
Protease that catalyzes two essential functions in the SUMO pathway (PubMed:11896061, PubMed:12192048, PubMed:15296745, PubMed:20194620, PubMed:21965678). The first is the hydrolysis of an alpha-linked peptide bond at the C-terminal end of the small ubiquitin-like modifier (SUMO) propeptides, SUMO1, SUMO2 and SUMO3 leading to the mature form of the proteins (PubMed:15296745). The second is the deconjugation of SUMO1, SUMO2 and SUMO3 from targeted proteins, by cleaving an epsilon-linked peptide bond between the C-terminal glycine of the mature SUMO and the lysine epsilon-amino group of the target protein (PubMed:15296745, PubMed:20194620, PubMed:21965678). May down-regulate CTNNB1 levels and thereby modulate the Wnt pathway (By similarity). Deconjugates SUMO2 from MTA1 (PubMed:21965678). Plays a dynamic role in adipogenesis by desumoylating and promoting the stabilization of CEBPB (PubMed:20194620). Acts as a regulator of the cGAS-STING pathway by catalyzing desumoylation of CGAS and STING1 during the late phase of viral infection (By similarity).
KIAA1331, SENP2, Sentrin-specific protease 2, Axam2, SMT3-specific isopeptidase 2, Sentrin/SUMO-specific protease SENP2, Smt3ip2
Rabbit Polyclonal SENP2 antibody. Suitable for WB, IHC-P, ICC/IF and reacts with Human samples. Cited in 1 publication. Immunogen corresponding to Synthetic Peptide within Human SENP2 aa 1-50.
pH: 7
Preservative: 0.01% Thimerosal (merthiolate)
Constituents: 78.99% PBS, 20% Glycerol (glycerin, glycerine), 1% BSA
SENP2 also known as Sentrin/SUMO-specific protease 2 functions as a protease that removes SUMO (Small Ubiquitin-like Modifier) moieties from target proteins. This activity regulates the sumoylation state of proteins affecting their stability activity and localization. SENP2 has a molecular mass of around 63 kDa. It is widely expressed in various tissues including the heart liver and placenta with particularly high levels in these areas suggesting its importance across different biological processes.
SUMO E3 ligase complexes often include SENP2 as an integral part. It modulates various signaling pathways by targeting transcription factors and other proteins involved in cellular stress response cell division and apoptosis. Through de-sumoylation SENP2 influences the activity of proteins by altering their transcriptional potency nuclear transport or protein degradation rates. SENP2's activity ensures appropriate cellular responses to environmental cues and maintains proper cellular homeostasis by balancing protein modifications.
SUMO-related mechanisms like nucleocytoplasmic transport and DNA repair involve SENP2. In these pathways SENP2 interacts with proteins like RanBP2 and PML contributing to cell cycle regulation and maintaining genomic stability. In the hypoxia response pathway SENP2's influence is important for modulating hypoxia-inducible factors (HIFs). These interactions illustrate SENP2’s regulatory roles in adapting cellular function in response to stress and changes in the cellular environment.
SENP2 displays relevance in cancer and cardiovascular disorders. Altered sumoylation activity linked with SENP2 is often observed in certain cancers where it may misregulate transcription factors like p53 and c-Myc. In cardiovascular diseases SENP2 interacts with proteins such as NFATc1 impacting cardiac development and function. These associations highlight SENP2's potential as a therapeutic target where modulation of its activity might offer novel treatment avenues for related diseases.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
7.5% SDS PAGE
All lanes: Western blot - Anti-SENP2 antibody (ab96865) at 1/1000 dilution
Lane 1: 293T whole cell lysate at 30 µg
Lane 2: MOLT-4 whole cell lysate at 30 µg
Predicted band size: 68 kDa
Immunofluorescence analysis of paraformaldehyde-fixed A431, using SENP2 antibody (ab96865) at 1/200 dilution. Lower image merged with DNA probe.
Immunohistochemical analysis of paraffin-embedded Cal27 xenograft, using SENP2 antibody (ab96865) at 1/500 dilution.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com